MCL-1–specific BH3 mimetics, which have entered clinical trials to treat MCL-1–dependent blood cancers like multiple myeloma (11–14), may also benefit from combination agents to broaden their therapeutic utility. This evidence concerns the gene MCL1 and plasma cell myeloma.